DexCom, Inc.
Strategic / Corporate Investor6340 Sequence Drive, United StatesSee on the mapdexcom.com
Dexcom is a medical technology company that develops glucose biosensing and continuous glucose monitoring products. Its technology is used to manage diabetes and track glucose and related health patterns.
- 2
- Portfolio companies on reccy
- 0
- Hiring now
- 0
- Open roles in the portfolio
- Nov 2024
- Latest portfolio round
Hiring now in the portfolio0
Apply on each company's siteNone of their companies on reccy has an open role right now. Browse all neurotech roles
Portfolio on reccy2
From company funding recordsTheir companies, round by round
From company funding records- ŌURAHelsinki, Finland; Oulu, Finland; San Francisco, CA; San Diego, CA
Wearables
- Jul 2026Series E
- Jul 2026Corporate
- Oct 2025Series E · $900M
- Sep 2025Debt · $250M
- Nov 2024Series D · $200MLed
- Apr 2022Venture Round
- EpitelSalt Lake City, Utah
EEG and neural monitoring · Wearables
- Jul 2026Series B · $26M
- Aug 2025Grant (prize money) · $7.6M
- Mar 2025Venture Round · $3.1M
- Feb 2022Series A · $12.5MLed
- Feb 2022Grant
- Dec 2019Seed
Rounds marked Led list DexCom, Inc. as a lead investor; the rest are the company's other funding.
Recent rounds in the portfolio
- Nov 2024
ŌURA · Series D $200MLead
With Fidelity Investments
- Feb 2022
Epitel · Series A $12.5MLead
With Catalyst Health Ventures, Genoa Ventures, Wavemaker Three-Sixty Health, OSF Ventures, MedMountain Ventures, Salt Lake City Angels
- Oct 2018
ŌURA · Series A $6MLead
With DFO Management, BOLD Capital Partners, Tesi, Gradient, Forerunner, Elysian Park Ventures, Lifeline Ventures, Fidelity Investments, TCG, Lateralus Holdings
Portfolio in the news
From the Cortex · last 12 months- Mar 2026ŌURA enters India with Oura Ring 4, reveals how the country sleeps
ŌURA · The Economic Times
- Mar 2026
- Jan 2026Jeff Huynh Joins Epitel as Director of Marketing
Epitel · Epitel on LinkedIn